Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Mai 2020 16:05 ET | Quelle: Brickell Biotech, Inc.

Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020

BOULDER, Colo., May 04, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
18. März 2020 16:01 ET | Quelle: Brickell Biotech, Inc.

Brickell Biotech Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

BOULDER, Colo., March 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
09. März 2020 16:05 ET | Quelle: Brickell Biotech, Inc.

Brickell Biotech to Report Fourth Quarter and Full Year 2019 Financial Results on March 18, 2020

BOULDER, Colo., March 09, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
04. März 2020 06:30 ET | Quelle: Brickell Biotech, Inc.

Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for Sofpironium Bromide

BOULDER, Colo., March 04, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
20. Februar 2020 06:30 ET | Quelle: Brickell Biotech, Inc.

Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology

BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
18. Februar 2020 06:30 ET | Quelle: Brickell Biotech, Inc.

Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements

BOULDER, Colo., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. and its subsidiary (collectively, “Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing...
10. Januar 2020 16:05 ET | Quelle: Brickell Biotech, Inc.

Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis

BOULDER, Colo., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
13. November 2019 16:05 ET | Quelle: Brickell Biotech, Inc.

Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update

BOULDER, Colo., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
30. Oktober 2019 16:42 ET | Quelle: Brickell Biotech, Inc.

Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest

NovaQuest temporarily suspended R&D funding payments Brickell filed a motion to dismiss the complaint filed by Bodor Labs and Nicholas S. Bodor in federal court Brickell initiated arbitration...
03. September 2019 06:45 ET | Quelle: Brickell Biotech

Brickell Biotech Completes Merger with Vical

Newly Nasdaq-listed BBI focused on developing differentiated therapeutics for treatment of dermatologic disorders Merger brings $60 Million in Combined Cash from Vical and R&D funding from...

Vorherige Seite